

Mark R Toshner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4296351/publications.pdf>

Version: 2024-02-01

117
papers

15,536
citations

53660

45
h-index

22102

113
g-index

128
all docs

128
docs citations

128
times ranked

25179
citing authors

#	ARTICLE	IF	CITATIONS
1	Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2002463.	3.1	31
2	Vascular Thrombosis in Severe COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Multicenter Study. <i>Critical Care Medicine</i> , 2022, 50, 624-632.	0.4	9
3	Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1102-1111.	2.5	35
4	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	13.7	756
5	The prognostic ability of cardiac output determined by inert gas rebreathing technique in pulmonary hypertension. <i>Chronic Respiratory Disease</i> , 2022, 19, 147997312210784.	1.0	1
6	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	1.9	7
7	The impact of hypoxia on B cells in COVID-19. <i>EBioMedicine</i> , 2022, 77, 103878.	2.7	15
8	Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19. <i>Thorax</i> , 2022, 77, 717-720.	2.7	16
9	Autoimmunity Is a Significant Feature of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 81-93.	2.5	9
10	Prevalence and clinical significance of conduction disease in patients with idiopathic pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 861-865.	0.3	1
11	Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1449-1460.	2.5	19
12	Bayesian Inference Associates Rare <i>KDR</i> Variants With Specific Phenotypes in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, .	1.6	29
13	EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study. <i>European Respiratory Journal</i> , 2021, 57, 2000124.	3.1	29
14	Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2003201.	3.1	25
15	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
16	Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus. <i>Cardiovascular Research</i> , 2021, 117, 2309-2325.	1.8	20
17	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. <i>Lancet, The</i> , 2021, 397, 605-612.	6.3	234
18	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979

#	ARTICLE	IF	CITATIONS
19	A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-9.	0.8	4
20	Single-cell multi-omics analysis of the immune response in COVID-19. <i>Nature Medicine</i> , 2021, 27, 904-916.	15.2	452
21	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
22	Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. <i>ELife</i> , 2021, 10, .	2.8	57
23	Challenges and opportunities for conducting a vaccine trial during the COVID-19 pandemic in the United Kingdom. <i>Clinical Trials</i> , 2021, 18, 615-621.	0.7	3
24	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	13.7	549
25	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	6.6	230
26	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1301-1326.	0.3	36
27	Rising COVID-19 related acute pulmonary emboli but falling national CTEPH referrals from a large national dataset. <i>ERJ Open Research</i> , 2021, 7, 00431-2021.	1.1	7
28	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
29	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	13.7	1,041
30	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
31	Positioning imatinib for pulmonary arterial hypertension: A phase I/II design comprising dose finding and single-arm efficacy. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	5
32	Serial right heart catheter assessment between balloon pulmonary angioplasty sessions identify procedural factors that influence response to treatment. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1223-1234.	0.3	23
33	Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2587-2597.	1.4	51
34	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	5.2	394
35	Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. <i>Nature Communications</i> , 2021, 12, 7104.	5.8	21
36	Characterization of GDF2 Mutations and Levels of BMP9 and BMP10 in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 575-585.	2.5	80

#	ARTICLE	IF	CITATIONS
37	A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 114-122.	1.9	81
38	CIPHER AND CIPHER-MRI: TWO PROSPECTIVE, MULTICENTER STUDIES FOR THE IDENTIFICATION OF BIOMARKER SIGNATURES FOR EARLY DETECTION OF PULMONARY HYPERTENSION. <i>Chest</i> , 2020, 158, A2191-A2193.	0.4	0
39	Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. <i>Cell Reports Medicine</i> , 2020, 1, 100062.	3.3	47
40	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020, 1, 100099.	3.3	61
41	Repurposing of medications for pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-12.	0.8	10
42	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. <i>BMJ Open</i> , 2020, 10, e044566.	0.8	11
43	Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 586-594.	2.5	45
44	Whole-genome sequencing of a sporadic primary immunodeficiency cohort. <i>Nature</i> , 2020, 583, 90-95.	13.7	148
45	CAMPOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 56, 1902096.	3.1	28
46	Whole-genome sequencing of patients with rare diseases in a national health system. <i>Nature</i> , 2020, 583, 96-102.	13.7	338
47	Response to letter to the Editor: Direct oral anticoagulants in thrombotic antiphospholipid syndrome associated with chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 756-757.	1.9	3
48	Response to: Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 759-761.	1.9	0
49	Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension: the UK experience. <i>Open Heart</i> , 2020, 7, e001144.	0.9	54
50	IL-6 in pulmonary hypertension: why novel is not always best. <i>European Respiratory Journal</i> , 2020, 55, 2000314.	3.1	21
51	Deprivation and prognosis in patients with pulmonary arterial hypertension: missing the effect of deprivation on a rare disease?. <i>European Respiratory Journal</i> , 2020, 56, 1902334.	3.1	1
52	CASPA (CArdiac Sarcoidosis in PAPworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000608.	1.2	3
53	Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. <i>ELife</i> , 2020, 9, .	2.8	423
54	Effective control of SARS-CoV-2 transmission between healthcare workers during a period of diminished community prevalence of COVID-19. <i>ELife</i> , 2020, 9, .	2.8	40

#	ARTICLE	IF	CITATIONS
55	Arrhythmic Burden and Outcomes in Pulmonary Arterial Hypertension. <i>Frontiers in Medicine</i> , 2019, 6, 169.	1.2	10
56	Chronic thromboembolic pulmonary hypertension following long-term peripherally inserted central venous catheter use. <i>Pulmonary Circulation</i> , 2019, 9, 1-3.	0.8	3
57	The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801805.	3.1	31
58	Bi-allelic Loss-of-Function CACNA1B Mutations in Progressive Epilepsy-Dyskinesia. <i>American Journal of Human Genetics</i> , 2019, 104, 948-956.	2.6	45
59	Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis. <i>European Respiratory Journal</i> , 2019, 53, 1801429.	3.1	31
60	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 227-238.	5.2	122
61	Myeloid angiogenic cells exhibit impaired migration, reduced expression of endothelial markers, and increased apoptosis in idiopathic pulmonary arterial hypertension. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019, 97, 306-312.	0.7	4
62	Limitations of resting haemodynamics in chronic thromboembolic disease without pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801787.	3.1	23
63	BMP9 Morphs into a Potential Player in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 819-821.	2.5	4
64	Tricuspid regurgitation and the right ventricle in risk stratification and timing of intervention. <i>Echo Research and Practice</i> , 2019, 6, R26-R40.	0.6	35
65	The outcome of reoperative pulmonary endarterectomy surgery. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2018, 26, 932-937.	0.5	11
66	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. <i>Nature Communications</i> , 2018, 9, 1416.	5.8	279
67	Clinical trial protocol for TRANSFORM-UK: A therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	0.8	67
68	Increased Antielastase Activity in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 652-655.	1.4	1
69	Loss-of-Function <i>ABCC8</i> Mutations in Pulmonary Arterial Hypertension. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002087.	1.6	62
70	Hematopoietic stem cell transplantation alters susceptibility to pulmonary hypertension in <i>Bmpr2</i> -deficient mice. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	6
71	De Novo Truncating Mutations in <i>WASF1</i> Cause Intellectual Disability with Seizures. <i>American Journal of Human Genetics</i> , 2018, 103, 144-153.	2.6	36
72	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. <i>American Journal of Human Genetics</i> , 2018, 103, 3-18.	2.6	46

#	ARTICLE	IF	CITATIONS
73	Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration. <i>American Journal of Human Genetics</i> , 2017, 100, 334-342.	2.6	26
74	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. <i>American Journal of Human Genetics</i> , 2017, 100, 75-90.	2.6	343
75	Phenotypic Characterization of <i>EIF2AK4</i> Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, 2022-2033.	1.6	111
76	The CRASH report: emergency management dilemmas facing acute physicians in patients with pulmonary arterial hypertension. <i>Thorax</i> , 2017, 72, 1035-1045.	2.7	30
77	The potential effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension responding to calcium channel blockade. <i>European Respiratory Journal</i> , 2017, 50, 1701141.	3.1	8
78	Plasma Metabolomics Implicates Modified Transfer RNAs and Altered Bioenergetics in the Outcomes of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 460-475.	1.6	154
79	Age should not be a barrier for pulmonary endarterectomy in carefully selected patients. <i>European Respiratory Journal</i> , 2017, 50, 1701804.	3.1	12
80	The pulmonary endothelium in acute respiratory distress syndrome: insights and therapeutic opportunities. <i>Thorax</i> , 2016, 71, 462-473.	2.7	169
81	Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy. <i>Circulation</i> , 2016, 133, 1761-1771.	1.6	307
82	HIF2 α -arginase axis is essential for the development of pulmonary hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 8801-8806.	3.3	140
83	Neutrophil Extracellular Traps Promote Angiogenesis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2078-2087.	1.1	158
84	Genetic testing in pulmonary hypertension: how should our clinical practice reflect recent advances?. <i>European Respiratory Journal</i> , 2016, 47, 388-389.	3.1	2
85	Generation and Culture of Blood Outgrowth Endothelial Cells from Human Peripheral Blood. <i>Journal of Visualized Experiments</i> , 2015, , e53384.	0.2	53
86	Bone Morphogenetic Protein Receptor Type II Deficiency and Increased Inflammatory Cytokine Production. A Gateway to Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 859-872.	2.5	113
87	The resistance-compliance product of the pulmonary circulation varies in health and pulmonary vascular disease. <i>Physiological Reports</i> , 2015, 3, e12363.	0.7	24
88	Hepatic Shunting of Eggs and Pulmonary Vascular Remodeling in <i>Bmpr2</i> ^{+/+} Mice with Schistosomiasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1355-1365.	2.5	23
89	Abstract 202: The Role of Neutrophil Extracellular Traps in the Pathogenesis of Pulmonary Hypertension.. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0
90	Transcript Analysis Reveals a Specific HOX Signature Associated with Positional Identity of Human Endothelial Cells. <i>PLoS ONE</i> , 2014, 9, e91334.	1.1	53

#	ARTICLE	IF	CITATIONS
91	Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. <i>European Respiratory Journal</i> , 2014, 44, 1635-1645.	3.1	205
92	Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. <i>Life Sciences</i> , 2014, 118, 391-396.	2.0	13
93	Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. <i>F1000prime Reports</i> , 2014, 6, 38.	5.9	15
94	Analyses of blood outgrowth endothelial cells reveal an endothelial HOX gene signature in human beings. <i>Lancet, The</i> , 2013, 381, S108.	6.3	1
95	Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H259-H264.	1.5	78
96	Reply to "Letter to the editor: Pulsatile pulmonary artery pressure: are fluid-filled catheters accurate in pulmonary hypertension?" <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H1682-H1682.	1.5	1
97	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. <i>Human Molecular Genetics</i> , 2013, 22, 3667-3679.	1.4	86
98	A Practical and Efficient Cellular Substrate for the Generation of Induced Pluripotent Stem Cells from Adults: Blood-Derived Endothelial Progenitor Cells. <i>Stem Cells Translational Medicine</i> , 2012, 1, 855-865.	1.6	54
99	Impaired Natural Killer Cell Phenotype and Function in Idiopathic and Heritable Pulmonary Arterial Hypertension. <i>Circulation</i> , 2012, 126, 1099-1109.	1.6	99
100	The fibrocyte in pulmonary hypertension: we seek him here, we seek him there. <i>European Respiratory Journal</i> , 2012, 39, 5-6.	3.1	3
101	Occlusion pressure analysis role in partitioning of pulmonary vascular resistance in CTEPH. <i>European Respiratory Journal</i> , 2012, 40, 612-617.	3.1	38
102	Risk of Potentially Life-Threatening Thyroid Dysfunction Due to Amiodarone in Idiopathic Pulmonary Arterial Hypertension Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 997-998.	1.2	7
103	Log ₁₀ Transformation Improves the Prognostic Value of Serial NT-proBNP Levels in Apparently Stable Pulmonary Arterial Hypertension. <i>Pulmonary Circulation</i> , 2011, 1, 244-249.	0.8	13
104	Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. <i>Thorax</i> , 2011, 66, 326-332.	2.7	82
105	Endothelial progenitor cells in pulmonary hypertension "dawn of cell-based therapy?". <i>International Journal of Clinical Practice</i> , 2010, 64, 7-12.	0.8	15
106	Pulmonary hypertension: advances in pathogenesis and treatment. <i>British Medical Bulletin</i> , 2010, 94, 21-32.	2.7	21
107	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 1171-1177.	2.5	331
108	Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 610-615.	0.3	18

#	ARTICLE	IF	CITATIONS
109	Evidence of Dysfunction of Endothelial Progenitors in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 780-787.	2.5	206
110	Fibrinogen AÂ Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2008, 31, 736-741.	3.1	83
111	Current differences in referral patterns for pulmonary endarterectomy in the UK. <i>European Respiratory Journal</i> , 2008, 32, 660-663.	3.1	8
112	NT-proBNP Does Not Rise on Acute Ascent to High Altitude. <i>High Altitude Medicine and Biology</i> , 2008, 9, 307-310.	0.5	20
113	Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2008, 134, 229-236.	0.4	226
114	Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertension. <i>Thorax</i> , 2007, 62, 617-622.	2.7	43
115	Role of NT-proBNP and 6MWD in chronic thromboembolic pulmonary hypertension. <i>Respiratory Medicine</i> , 2007, 101, 2254-2262.	1.3	50
116	Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). <i>Vascular Pharmacology</i> , 2007, 46, 449-455.	1.0	35
117	Treatment options in pulmonary arterial hypertension. <i>Future Prescriber</i> , 2007, 8, 5-8.	0.1	0